Supplementary material

Bacharach J, Tatham A, Ferguson G, Belalcázar S, Thieme H, Goodkin ML, Chen MY, Guo Q, Liu J, Robinson MR, Bejanian M, Wirta DL; on behalf of the ARTEMIS 2 Study Group. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). *Drugs*.

Author for correspondence: Jason Bacharach, MD; North Bay Eye Associates, Petaluma, CA, USA; Email: jbacharach@northbayeye.com

Online Resource 3



Mean IOP through 12 weeks after the second and third administration. LS mean IOP in the study eye from a mixed-effect model for repeated measures after (a) the second administration and (b) the third administration. The 95% CIs of the between-group differences show that both the 10- and 15-µg bimatoprost implants met the prespecified criteria for statistical and clinical noninferiority to timolol BID after the second administration (c) and after the third administration (d). *BID* twice daily, *Bim* bimatoprost, *CI* confidence interval, *IOP* intraocular pressure, *LS* least-squares